| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2010PNAS..107..181V |
| P356 | DOI | 10.1073/PNAS.0912914107 |
| P932 | PMC publication ID | 2806760 |
| P698 | PubMed publication ID | 20018688 |
| P5875 | ResearchGate publication ID | 40696052 |
| P50 | author | Barton Haynes | Q4865631 |
| Garnett Kelsoe | Q60614752 | ||
| Marilyn Diaz | Q64621170 | ||
| Hua-Xin Liao | Q88608388 | ||
| Laurent Verkoczy | Q88773002 | ||
| Munir Alam | Q89520930 | ||
| Hilary Bouton-Verville | Q117248645 | ||
| Ying-Bin Ouyang | Q117248646 | ||
| P2093 | author name string | T Matt Holl | |
| P2860 | cites work | Resolution of Three Nonproliferative Immature Splenic B Cell Subsets Reveals Multiple Selection Points During Peripheral B Cell Maturation | Q43819902 |
| Editors and editing of anti-DNA receptors. | Q43832072 | ||
| Specific phospholipid recognition by human immunodeficiency virus type-1 neutralizing anti-gp41 2F5 antibody | Q45417674 | ||
| Difficulties in eliciting broadly neutralizing anti-HIV antibodies are not explained by cardiolipin autoreactivity | Q46168513 | ||
| Structural basis of enhanced binding of extended and helically constrained peptide epitopes of the broadly neutralizing HIV-1 antibody 4E10. | Q51100729 | ||
| The site and stage of anti-DNA B-cell deletion. | Q52210540 | ||
| Expression of anti-DNA immunoglobulin transgenes in non-autoimmune mice | Q59065295 | ||
| Immunoglobulin heavy chain gene replacement: a mechanism of receptor editing | Q71457193 | ||
| Heavy chain variable region, light chain variable region, and heavy chain CDR3 influences on the mono- and polyreactivity and on the affinity of human monoclonal rheumatoid factors | Q72169101 | ||
| Deletion and editing of B cells that express antibodies to DNA | Q72273763 | ||
| Editing disease-associated autoantibodies | Q73115270 | ||
| Antigen receptor editing in anti-DNA transitional B cells deficient for surface IgM | Q81119886 | ||
| Selection of anti-double-stranded DNA B cells in autoimmune MRL-lpr/lpr mice | Q83169995 | ||
| Development and selection of edited B cells in B6.56R mice | Q83367336 | ||
| Antibody vs. HIV in a clash of evolutionary titans | Q24536059 | ||
| Structural definition of a conserved neutralization epitope on HIV-1 gp120 | Q24655948 | ||
| Pathophysiology of the antiphospholipid syndrome | Q28267421 | ||
| Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial | Q28972526 | ||
| Antibody neutralization and escape by HIV-1 | Q29547345 | ||
| Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies | Q29614531 | ||
| Rapid evolution of the neutralizing antibody response to HIV type 1 infection | Q29618603 | ||
| Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety data | Q31140424 | ||
| Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers | Q33444658 | ||
| Two distinct populations of H chain-edited B cells show differential surrogate L chain dependence | Q33552573 | ||
| A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1 | Q34306804 | ||
| The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes | Q34610233 | ||
| In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth | Q34937404 | ||
| Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques | Q35101333 | ||
| Immunoglobulin heavy chain expression shapes the B cell receptor repertoire in human B cell development | Q36041356 | ||
| Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow | Q36230070 | ||
| Autoreactive B cells in the marginal zone that express dual receptors | Q36369869 | ||
| The Cellular Location of Self-antigen Determines the Positive and Negative Selection of Autoreactive B Cells | Q36371832 | ||
| Antibody polyspecificity and neutralization of HIV-1: a hypothesis | Q36487151 | ||
| Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. | Q36600380 | ||
| Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys | Q36628390 | ||
| Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. | Q36634499 | ||
| Early preplasma cells define a tolerance checkpoint for autoreactive B cells | Q37006531 | ||
| Sites and stages of autoreactive B cell activation and regulation. | Q37058621 | ||
| Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm | Q37247974 | ||
| Role of HIV membrane in neutralization by two broadly neutralizing antibodies | Q37453499 | ||
| Heavy chain-only antibodies are spontaneously produced in light chain-deficient mice. | Q40034320 | ||
| Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. | Q40429324 | ||
| Genetic and structural evidence for antigen selection of anti-DNA antibodies. | Q40661152 | ||
| Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice. | Q41423746 | ||
| Analysis of the structural correlates for antibody polyreactivity by multiple reassortments of chimeric human immunoglobulin heavy and light chain V segments | Q41886151 | ||
| In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl. IV. Affinity-dependent, antigen-driven B cell apoptosis in germinal centers as a mechanism for maintaining self-tolerance | Q41888015 | ||
| Breakdown of self-tolerance in anergic B lymphocytes. | Q43668436 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | 181-186 | |
| P577 | publication date | 2009-12-14 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance | |
| P478 | volume | 107 |
| Q30234577 | A Little Help From the Follicles: Understanding the Germinal Center Response to Human Immunodeficiency Virus 1 Infection and Prophylactic Vaccines |
| Q64075176 | A Pathogenic Role for Splenic B1 Cells in SIV Disease Progression in Rhesus Macaques |
| Q34396912 | A fusion intermediate gp41 immunogen elicits neutralizing antibodies to HIV-1 |
| Q27676864 | A gp41 MPER-specific Llama VHH Requires a Hydrophobic CDR3 for Neutralization but not for Antigen Recognition |
| Q40220988 | A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles |
| Q35825170 | A systematic review of syphilis serological treatment outcomes in HIV-infected and HIV-uninfected persons: rethinking the significance of serological non-responsiveness and the serofast state after therapy |
| Q34170264 | AIDS/HIV. Host controls of HIV neutralizing antibodies |
| Q35382871 | Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors |
| Q52582170 | Anti-HIV-1 B cell responses are dependent on B cell precursor frequency and antigen-binding affinity. |
| Q38986943 | Anti-MPER antibodies with heterogeneous neutralization capacity are detectable in most untreated HIV-1 infected individuals. |
| Q39108751 | Antibody-virus co-evolution in HIV infection: paths for HIV vaccine development |
| Q34774808 | Architectural insight into inovirus-associated vectors (IAVs) and development of IAV-based vaccines inducing humoral and cellular responses: implications in HIV-1 vaccines |
| Q27680125 | Autoreactivity and Exceptional CDR Plasticity (but Not Unusual Polyspecificity) Hinder Elicitation of the Anti-HIV Antibody 4E10 |
| Q34022578 | Autoreactivity in HIV-1 broadly neutralizing antibodies: implications for their function and induction by vaccination |
| Q34645502 | B cell responses to HIV-1 infection and vaccination: pathways to preventing infection |
| Q91724262 | B cell signaling in context |
| Q34273373 | B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study |
| Q37669385 | BCR and Endosomal TLR Signals Synergize to Increase AID Expression and Establish Central B Cell Tolerance |
| Q36016522 | BLyS-mediated modulation of naive B cell subsets impacts HIV Env-induced antibody responses |
| Q46226616 | Bacterially derived synthetic mimetics of mammalian oligomannose prime antibody responses that neutralize HIV infectivity. |
| Q42682810 | Bill and Melinda Gates honored with Lasker~Bloomberg Public Service Award |
| Q38683449 | Breaching peripheral tolerance promotes the production of HIV-1-neutralizing antibodies |
| Q91812746 | Broadly Neutralizing Antibodies against HIV: Back to Blood |
| Q40679052 | Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design |
| Q38811735 | Broadly neutralizing antibodies: An approach to control HIV-1 infection |
| Q35923859 | Can immunological principles and cross-disciplinary science illuminate the path to vaccines for HIV and other global health challenges? |
| Q47095100 | Circulating Plasmablasts from Chronically Human Immunodeficiency Virus-Infected Individuals Predominantly Produce Polyreactive/Autoreactive Antibodies |
| Q37049675 | Common Tolerance Mechanisms, but Distinct Cross-Reactivities Associated with gp41 and Lipids, Limit Production of HIV-1 Broad Neutralizing Antibodies 2F5 and 4E10 |
| Q90629708 | Conditional antibody expression to avoid central B cell deletion in humanized HIV-1 vaccine mouse models |
| Q55265892 | Conformational Plasticity in Broadly Neutralizing HIV-1 Antibodies Triggers Polyreactivity. |
| Q84258774 | Conformation‐specific Display of 4E10 and 2F5 Epitopes on Self‐assembling Protein Nanoparticles as a Potential HIV Vaccine |
| Q57186351 | Control of autoreactive B cells by IgM and IgD B cell receptors: maintaining a fine balance |
| Q46826498 | Curiouser and curiouser: the role(s) of AID expression in self-tolerance |
| Q35640984 | DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers |
| Q92184345 | Detection and activation of HIV broadly neutralizing antibody precursor B cells using anti-idiotypes |
| Q38959483 | Differential reactivity of germ line allelic variants of a broadly neutralizing HIV-1 antibody to a gp41 fusion intermediate conformation |
| Q37730206 | Enhanced antibody responses to an HIV-1 membrane-proximal external region antigen in mice reconstituted with cultured lymphocytes |
| Q43942291 | Enhanced expression of HIV and SIV vaccine antigens in the structural gene region of live attenuated rubella viral vectors and their incorporation into virions |
| Q34016211 | Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies |
| Q33924272 | Epitope target structures of Fc-mediated effector function during HIV-1 acquisition |
| Q37427477 | Functional Versatility of AGY Serine Codons in Immunoglobulin Variable Region Genes |
| Q38992744 | Genetic and structural analyses of affinity maturation in the humoral response to HIV-1. |
| Q37683120 | HIV Diagnosis and Treatment through Advanced Technologies |
| Q40449984 | HIV-1 Envelope Mimicry of Host Enzyme Kynureninase Does Not Disrupt Tryptophan Metabolism. |
| Q27022055 | HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design |
| Q64934974 | HIV-1 autoreactive antibodies: are they good or bad for HIV-1 prevention? |
| Q35172770 | HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development |
| Q26765966 | HIV-Host Interactions: Implications for Vaccine Design |
| Q27000480 | HIV‐1 neutralizing antibodies: understanding nature's pathways |
| Q39617158 | Hepatitis B Virus Surface Antigen Assembly Function Persists when Entire Transmembrane Domains 1 and 3 Are Replaced by a Heterologous Transmembrane Sequence |
| Q39108769 | Host controls of HIV broadly neutralizing antibody development |
| Q39108735 | Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies |
| Q30234773 | Humanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem |
| Q34324992 | Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies |
| Q38220506 | Immune System Regulation in the Induction of Broadly Neutralizing HIV-1 Antibodies |
| Q89790825 | Immune checkpoint modulation enhances HIV-1 antibody induction |
| Q40103798 | Immune perturbations in HIV-1-infected individuals who make broadly neutralizing antibodies |
| Q41925820 | Immunologic Insights on the Membrane Proximal External Region: A Major Human Immunodeficiency Virus Type-1 Vaccine Target. |
| Q39108760 | Immunologic characteristics of HIV-infected individuals who make broadly neutralizing antibodies. |
| Q27312171 | Induction of Antibodies in Rhesus Macaques That Recognize a Fusion-Intermediate Conformation of HIV-1 gp41 |
| Q42278743 | Induction of HIV-1 broad neutralizing antibodies in 2F5 knock-in mice: selection against membrane proximal external region-associated autoreactivity limits T-dependent responses |
| Q34540645 | Induction of immunity to human immunodeficiency virus type-1 by vaccination |
| Q47118310 | Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations |
| Q37221575 | Initiation of immune tolerance-controlled HIV gp41 neutralizing B cell lineages |
| Q35043547 | Is developing an HIV-1 vaccine possible? |
| Q36839817 | Lessons learned from HIV-1 vaccine trials: new priorities and directions |
| Q37361294 | Live attenuated rubella vectors expressing SIV and HIV vaccine antigens replicate and elicit durable immune responses in rhesus macaques |
| Q42284964 | Live attenuated rubella viral vectors stably express HIV and SIV vaccine antigens while reaching high titers |
| Q27644415 | Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody |
| Q42346870 | Meeting report VLPNPV: Session 5: Plant based technology |
| Q90323195 | Minding the gap: The impact of B-cell tolerance on the microbial antibody repertoire |
| Q51488892 | Model for competition from self during passive immunization, with application to broadly neutralizing antibodies for HIV |
| Q37607358 | Modulation of nonneutralizing HIV-1 gp41 responses by an MHC-restricted TH epitope overlapping those of membrane proximal external region broadly neutralizing antibodies |
| Q35904501 | Monoclonal Antibody-Based Candidate Therapeutics Against HIV Type 1 |
| Q36568026 | Mouse marginal zone B cells harbor specificities similar to human broadly neutralizing HIV antibodies |
| Q42170072 | Nonneutralizing HIV-1 gp41 envelope cluster II human monoclonal antibodies show polyreactivity for binding to phospholipids and protein autoantigens |
| Q38097613 | On the benefits of sin: can greater understanding of the 1F7-idiotypic repertoire freeze enhance HIV vaccine development? |
| Q57157197 | One-step CRISPR/Cas9 method for the rapid generation of human antibody heavy chain knock-in mice |
| Q64984736 | Poly- and autoreactivity of HIV-1 bNAbs: implications for vaccine design. |
| Q37951868 | Polyreactive antibodies in adaptive immune responses to viruses |
| Q34992787 | Polyreactivity and autoreactivity among HIV-1 antibodies |
| Q40092127 | Potent and broad HIV-neutralizing antibodies in memory B cells and plasma |
| Q56600657 | Progress in HIV-1 vaccine development |
| Q27693849 | Progress in HIV-1 vaccine development. |
| Q37549777 | Progress toward active or passive HIV-1 vaccination |
| Q33778466 | Prolonged exposure of the HIV-1 gp41 membrane proximal region with L669S substitution |
| Q33937285 | Rational antibody-based HIV-1 vaccine design: current approaches and future directions |
| Q42132261 | Reactivity profiles of broadly neutralizing anti-HIV-1 antibodies are distinct from those of pathogenic autoantibodies |
| Q33835034 | Redemption of autoreactive B cells |
| Q86408281 | Report of the Cent Gardes HIV Vaccine Conference the B-cell Response to HIV. Part 1: Broadly Neutralizing Antibodies Fondation Mérieux Conference Center, Veyrier du Lac, France, 5–7 November 2012 |
| Q35336374 | Rescue of HIV-1 broad neutralizing antibody-expressing B cells in 2F5 VH x VL knockin mice reveals multiple tolerance controls |
| Q26852927 | Resolve, revise, and relax: The 3 Rs of B cell repertoire adjustment |
| Q39206970 | Role of germinal centers for the induction of broadly-reactive memory B cells |
| Q38046828 | Role of human immunodeficiency virus type 1 envelope structure in the induction of broadly neutralizing antibodies. |
| Q35116581 | Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies |
| Q64888160 | Self-tolerance curtails the B cell repertoire to microbial epitopes. |
| Q91609981 | Strategies for inducing effective neutralizing antibody responses against HIV-1 |
| Q27677011 | Structural basis for HIV-1 gp120 recognition by a germ-line version of a broadly neutralizing antibody |
| Q26829461 | Structural insights on the role of antibodies in HIV-1 vaccine and therapy |
| Q27660384 | Structure of a clade C HIV-1 gp120 bound to CD4 and CD4-induced antibody reveals anti-CD4 polyreactivity |
| Q27681501 | Structure of an HIV-1-neutralizing antibody target, the lipid-bound gp41 envelope membrane proximal region trimer |
| Q59353231 | Structure of the membrane proximal external region of HIV-1 envelope glycoprotein |
| Q37617455 | Sublingual Priming with a HIV gp41-Based Subunit Vaccine Elicits Mucosal Antibodies and Persistent B Memory Responses in Non-Human Primates |
| Q64281085 | The Chimpanzee SIV Envelope Trimer: Structure and Deployment as an HIV Vaccine Template |
| Q52581587 | The development of HIV vaccines targeting gp41 membrane-proximal external region (MPER): challenges and prospects |
| Q64379779 | The gp41 epitope, QARVLAVERY, is highly conserved and a potent inducer of IgA that neutralizes HIV-1 and inhibits viral transcytosis |
| Q38209477 | The maturation of antibody technology for the HIV epidemic |
| Q34399656 | The stem of vesicular stomatitis virus G can be replaced with the HIV-1 Env membrane-proximal external region without loss of G function or membrane-proximal external region antigenic properties. |
| Q42051255 | Uncommon structural motifs dominate the antigen binding site in human autoantibodies reactive with basement membrane collagen |
| Q33907538 | Variable epitope libraries: New vaccine immunogens capable of inducing broad human immunodeficiency virus type 1-neutralizing antibody response |
| Q27676728 | Viral Escape from Neutralizing Antibodies in Early Subtype A HIV-1 Infection Drives an Increase in Autologous Neutralization Breadth |
| Q40166335 | What Are the Primary Limitations in B-Cell Affinity Maturation, and How Much Affinity Maturation Can We Drive with Vaccination? Breaking through Immunity's Glass Ceiling |
| Q92916578 | Widespread B cell perturbations in HIV-1 infection afflict naive and marginal zone B cells |
Search more.